Clinical Trials Logo

Oncology clinical trials

View clinical trials related to Oncology.

Filter by:

NCT ID: NCT01439152 Completed - Oncology Clinical Trials

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Start date: September 7, 2011
Phase: Phase 1
Study type: Interventional

BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.

NCT ID: NCT01345019 Completed - Cancer Clinical Trials

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Start date: May 17, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.

NCT ID: NCT01300026 Completed - Cancer Clinical Trials

AMG 319 Lymphoid Malignancy FIH

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts. The dose exploration in part 1, studies cohorts of 3 subjects with relapsed or refractory lymphoid malignancies and uses a practical continuous reassessment model [CRM] to guide dose escalation and to define the MTD. The dose expansion in part 2 will enroll 20 subjects with CLL at a dose no higher than the MTD and further explore the safety, PK, and clinical activity of AMG 319 in this patient population.

NCT ID: NCT01253707 Completed - Cancer Clinical Trials

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Start date: December 8, 2010
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.

NCT ID: NCT00813384 Completed - Cancer Clinical Trials

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Start date: December 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.

NCT ID: NCT00807859 Completed - Breast Cancer Clinical Trials

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Start date: March 9, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab (cohort A) or with capecitabine and lapatinib (cohort B). Study part 2 is cohort expansion of the tolerable doses determined in part 1.

NCT ID: NCT00770536 Completed - Cancer Clinical Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion. It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.

NCT ID: NCT00752570 Completed - Cancer Clinical Trials

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.

NCT ID: NCT00630786 Completed - Colorectal Cancer Clinical Trials

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

NCT ID: NCT00588289 Completed - Oncology Clinical Trials

Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA

Start date: September 1999
Phase: N/A
Study type: Observational

This protocol is not an independent research study, but rather a means to aggregate Children's Cancer Group protocols that are closed to patient entry for the purpose of collecting current status information on those patients treated under those protocols.